Navigation Links
Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Date:9/4/2007

ckages, while the Taxus Stent was used in 669 patients and 941 artery blockages.

Cordis Corporation sponsored the REALITY Trial.

About the CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients.

Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of sirolimus-eluting stent, the CYPHER SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. The CYPHER SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States.

For more complete information on indications, contraindications, warnings and precautions, see the Instructions for Use available at http://www.cypherstent.com.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at http://www.cordis.com.

*Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vas
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-year data for Angiotechs Vascular Wrap Paclitaxel-Eluting Mesh to be Presented at European Vascular Symposium
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
5. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
8. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
9. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
10. Urinalysis Analyzers: Large Capabilities in Every Size Device
11. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... CUPERTINO, Calif., March 2, 2015  DURECT Corporation (Nasdaq: ... the three months ended December 31, 2014. Total revenues ... 31, 2014 and for the three months ended December ... three months ended December 31, 2014 as compared to ... period in 2013.Total revenues were $19.4 million and net ...
(Date:3/2/2015)... , March 2, 2015 When someone gets ... head to a primary care physician or an urgent ... majority of the healthcare provided by doctors and medical ... works, but it,s not ideal in every circumstance. Though ... actually locations where occupants have higher chances of contracting ...
(Date:3/2/2015)... March 2, 2015  Champions Oncology, Inc. (OTC-PINK: CSBR), ... solutions and services to personalize the development and use ... on the $2 million convertible promissory notes with two ... Dr. David Sidransky , chairman ... benefit from the confidence and commitment of our two ...
Breaking Medicine Technology:DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12House Call Medicine Helps Patients Receive Treatment While Avoiding the Hassles and Potential Risks of an Urgent Care Facility 2Champions Oncology Extends Convertible Debt Financing 2Champions Oncology Extends Convertible Debt Financing 3
... risk of cardiovascular hospitalization or death by 24 percent ... Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New ... the ATHENA trial was published in the New England ... in addition to standard therapy, significantly reduced the risk ...
... treatment decisionsANN ARBOR, Mich., Feb. 11 Researchers from ... have identified a panel of small molecules, or metabolites, ... lead to a simple test that would help doctors ... immediate, aggressive treatment.Results of the study appear in the ...
Cached Medicine Technology:New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 2New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 3New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 4New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 5New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation 6Researchers Discover Metabolite Linked to Aggressive Prostate Cancer 2Researchers Discover Metabolite Linked to Aggressive Prostate Cancer 3
(Date:3/2/2015)... (PRWEB) March 02, 2015 A ... scandal deviating from the typical nip slip or scathing ... movie industry is dawning the streets of Hollywood as ... questions about drug addiction and substance abuse in Hollywood. ... constructed to take a political stance on the travails ...
(Date:3/2/2015)... FL (PRWEB) March 02, 2015 While ... with Title VI of the Civil Rights Act, the ... and hearing loss are bringing light to the value ... statistics reveal that nearly 1 in 20 U.S. children ... in 10 in some major cities.(1) Stratus Video ...
(Date:3/2/2015)... 2015 Robins & Morton Celebrates Women ... Women in Construction Week (March 1-7, sponsored by the ... National Women’s History Month, Robins & Morton is recognizing ... company and the construction industry as a whole. From ... dozens of roles in between, each woman has a ...
(Date:3/2/2015)... 2015 Over the last five years ... vendors seeking to expand their geographic presence and achieve ... to reach $6.2 billion by 2019 at CAGR of ... the U.S. and Canada and a major part of ... regions such as Asia-Pacific including China and India, Latin ...
(Date:3/2/2015)... March 02, 2015 Dinner preparation ... thanks to the success of DinnerDork , ... easy and delicious for thousands of busy customers. ... feedback by expanding to offer a total of ... features seasonally appropriate classic recipes and comfort foods; ...
Breaking Medicine News(10 mins):Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 2Health News:Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 2Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 3Health News:Stratus Video Addresses Inadequate Language Interpreting for 2.4 Million U.S. Children 4Health News:Robins & Morton Recognizes Women In Construction 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3
... Price of Diabetes Prevention Far Less ... , BETHESDA, Md., Aug. 18 The ... has been misconstrued during recent health care reform discussions, according ... professional organization of doctors of podiatric medicine (DPMs), also known ...
... , WASHINGTON, Aug. 18 300,000 American women with ... US had adopted a British-style, government-run health care system. This ... Oncology, appears in a TV ad launched today by The Independent ... women. The 60-second spot highlights the deadly risks to women ...
... , , ... cell volume measurement in the flexographic printing industry, will be ... is a highly versatile, lightweight instrument that is extremely accurate ... The MicroDynamics QC line of inspection microscopes have a reputation ...
... Institutes of Health have found that the activity of a ... aggressive brain cancer called glioblastoma multiforme (GBM). In a move ... can block this activity and reduce the spreading of GBM ... lethal form of brain cancer, with about half of patients ...
... Aug. 18 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) ... pleased to report that its clinical trial is currently being ... September (Approx 60 days). The company expects the manufacturing license ... , H1N1 (referred to as "swine flu" early on) is ...
... , LOS ANGELES, Aug. 18 On THURSDAY, ... organization committed to improving the quality of life for Latino children ... gala, " EL SUENO DE ESPERANZA " at the Hollywood Palladium. ... children and families, while at the same time raise funds for ...
Cached Medicine News:Health News:American Podiatric Medical Association Corrects President's Misstatement on Foot Amputation Costs 2Health News:Women Speak Out Against Government Takeover of Health Care 2Health News:Women Speak Out Against Government Takeover of Health Care 3Health News:NIH researchers identify key factor that stimulates brain cancer cells to spread 2Health News:NIH researchers identify key factor that stimulates brain cancer cells to spread 3Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 2Health News:Hard To Treat Diseases (HTDS.PK) H1N1 Swine Flu Clinical Trial 3Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 2Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 3Health News:Eva Longoria Parker and George Lopez Return to Host 9th Annual PADRES' Contra El Cancer's 'EL SUENO DE ESPERANZA' Gala 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: